Nucleic Acids Res:武大杜海宁课题组发现核蛋白在应急条件下的自噬降解新途径

2017-03-19 佚名 武汉大学生命科学学院

近日,国际著名学术期刊Nucleic Acids Research (IF:9.202)在线发表了武汉大学杜海宁课题组的最新研究成果。论文题目为“Gcn5-mediated Rph1 acetylation regulates its autophagic degradation under DNA Damage Stress”(乙酰转移酶Gcn5介导的乙酰化修饰调控组蛋白去甲基化酶Rph1在DN

近日,国际著名学术期刊Nucleic Acids Research (IF:9.202)在线发表了武汉大学杜海宁课题组的最新研究成果。论文题目为“Gcn5-mediated Rph1 acetylation regulates its autophagic degradation under DNA Damage Stress”(乙酰转移酶Gcn5介导的乙酰化修饰调控组蛋白去甲基化酶Rph1在DNA损伤应急下的自噬降解)。博士生李锋为论文的第一作者,杜海宁教授为论文的通讯作者,研究生郑亮德、陈欣,武大生命科学院的赵晓璐副教授和美国普渡大学的Scott D. Briggs教授共同参与了该项研究。



许多与损伤修复相关基因的表达在细胞生命过程中被严格调控:在正常条件下表达被抑制,而在DNA损伤刺激下表达被激活。组蛋白去甲基化酶Rph1可以抑制很多环境应急及自噬相关基因的表达,但是Rph1在应急条件下是如何被调控的尚不清楚。课题组的研究人员发现,在DNA损伤刺激下,酿酒酵母中的组蛋白修饰酶Rph1会通过自噬途径降解,以解除对DNA损伤基因的抑制。乙酰转移酶Gcn5介导的乙酰化修饰能够有效调控Rph1的出核过程并进入胞质中的自噬体进行蛋白质降解。这种调控机制对于DNA损伤信号通路的激活和细胞内稳态环境的维持都是必需的。我们的研究提示,乙酰化介导的自噬降解途径很可能代表着一种清除受损细胞器和DNA损伤修复相关抑制因子的广泛机制。

该研究得到了国家自然科学基金、国家重大科学研究计划、湖北省自然科学基金和武汉大学大型仪器开放补贴的资助。

原始出处:
Feng Li, Liang-De Zheng, Xin Chen,et al. Gcn5-mediated Rph1 acetylation regulates its autophagic degradation under DNA damage stress. Nucleic Acids Res 2017

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1986081, encodeId=6016198608113, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 17 12:59:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911418, encodeId=4651191141839, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Wed Aug 02 13:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991577, encodeId=8ce719915e74e, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sat Sep 16 06:59:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953365, encodeId=ab3019533654d, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Nov 07 08:59:00 CST 2017, time=2017-11-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1986081, encodeId=6016198608113, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 17 12:59:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911418, encodeId=4651191141839, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Wed Aug 02 13:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991577, encodeId=8ce719915e74e, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sat Sep 16 06:59:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953365, encodeId=ab3019533654d, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Nov 07 08:59:00 CST 2017, time=2017-11-07, status=1, ipAttribution=)]
    2017-08-02 wodejia-dayu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1986081, encodeId=6016198608113, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 17 12:59:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911418, encodeId=4651191141839, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Wed Aug 02 13:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991577, encodeId=8ce719915e74e, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sat Sep 16 06:59:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953365, encodeId=ab3019533654d, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Nov 07 08:59:00 CST 2017, time=2017-11-07, status=1, ipAttribution=)]
    2017-09-16 xlxchina
  4. [GetPortalCommentsPageByObjectIdResponse(id=1986081, encodeId=6016198608113, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 17 12:59:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911418, encodeId=4651191141839, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Wed Aug 02 13:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991577, encodeId=8ce719915e74e, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sat Sep 16 06:59:00 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953365, encodeId=ab3019533654d, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Nov 07 08:59:00 CST 2017, time=2017-11-07, status=1, ipAttribution=)]

相关资讯

神经病理性疼痛中自噬的参与以及高压氧对其调节的展望

 1.神经病理性疼痛 神经病理性疼痛定义为由躯体感觉神经系统的损伤和疾病而直接造成的疼痛。神经病理性痛发病率高,患病率约为3.3%~8.2%,并且严重缩减患者的健康寿命年。而当前神经病理性疼痛的治疗并不能获得令人满意的效果,超过2/3的患者不能获得有效减轻疼痛的治疗。不可否认,疼痛,尤其是难以治疗的神经病理性疼痛成为影响人类健康以及生活质量的重要因素。 外周机制、

Nature:“青年干细胞”和“老年干细胞”是如何维持代谢和功能的呢?

随着年龄的增长,造血干细胞失去了再生血液系统的能力,并且促进了疾病的发展。自噬与健康和寿命相关,并且对于保护造血干细胞免受代谢应激损伤至关重要。近期,一项发表在权威杂志Nature上的文章显示了造血干细胞自噬的丧失导致线粒体以及激活代谢状态的累积,以此通过表观遗传调控驱动加速骨髓的分化,并损害造血干细胞自我更新能力和再生潜力。尤其引人注目的是,老年小鼠中的大多数造血干细胞分担这些发生变化的代谢和功

CHEST:西罗莫司和自噬抑制对LAM治疗效果的I期临床试验

动物和细胞研究支持抑制自噬在淋巴管平滑肌瘤病(LAM)中的重要性。近期,一项发表在杂志CHEST上的研究在具有LAM的受试者队列中,测试了2种不同剂量水平下使用西罗莫司和羟基氯喹(自噬抑制剂)治疗的安全性和耐受性。此外还研究了肺功能的变化。此项为期48周、2个中心的I期试验评估了予以≥18岁的LAM患者每日两次逐渐增高的口服羟氯喹剂量(100-200mg)联合西罗莫司的安全性。受试者接受联合治疗2

高等真核生物细胞中监测自噬试验方法的解释与使用指南(上)

白水解通量而得到证实。这种方法的一个优点是不需要自噬抑制剂或溶酶体抑制剂来阻断LC3-II的降解。注意   在测量LC3-IIs/LC3-I时的一点重要说明即这种方法是否也适用于其它类型的细胞中还不清楚,而且在许多标准化的细胞类型中,如HeLa, HEK293和PC12,没有观察到溶解形态的LC3-II。此外,同样的顾虑适用于用western印迹的方法检测LC3-I。需要注意的

Autophagy:浙江大学周继勇课题组阐释狂犬病毒复制的自噬机制

2017年2月23日,国际著名自噬领域学术期刊《Autophagy》在线发表在线发表了浙江大学动物科学学院农业部动物病毒学重点实验室周继勇教授课题组题为“BECN1-dependent CASP2 incomplete autophagy induction by binding to rabies virus phosphoprotein”的论文。

Nature:重磅!癌症微环境自噬促进肿瘤生长

在一项新的研究中,来自挪威、匈牙利和美国的研究人员发现癌细胞通过窃取周围细胞的能量进行生长。